Technical Data
U1820-14
Urokinase Plasminogen Activator (uPA)
Description:
Urokinase plasminogen activator (uPA) is a serine protease. It converts the abundant proenzyme plasminogen to active plasmin and plays a key role in cancer invasion and a variety of tissue remodelling processes such as wound healing, mammary gland involution and placental development(1-3). Elevated levels of uPA are associated with poor prognosis in many types of cancer (2-5).

Applications:
Suitable for use in ELISA, Western blot and Immunohistochemistry. Other applications have not been tested.

Recommended Dilutions:
Western Blot: under reduced and non-reducing conditions
Immunohistochemistry (frozen sections): 1:25
Optimal dilutions to be determined by the researcher.

Culture Medium:
RPMI 1640 with 10% fetal calf serum

Hybridoma:
NS1/AG4.1 myeloma cells with spleen cells from Balb/c mice.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG19B14Affinity Purified
SizeStorageShippingSourceHost
100ul-20°CBlue IceHumanMouse
Concentration:
~1mg/ml
Immunogen:
Native human uPA
Purity:
Purified by Protein A/G affinity chromatography.
Form
Supplied as a liquid in PBS, pH7.4, 15mM sodium azide.
Specificity:
Recognizes the A-chain of human uPA. Binds single and two-chain uPA, uPA/PAI-1 complex and uPA/uPAR complex. A reaction isseen with the amino terminal fragment (ATF) but not with LMW uPA. It inhibits the enzymatic activity of uPA in the fibrin plate assay. No reaction with human tissue plasminogen activator (tPA) or with any other human plasma proteins.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Danø K, et al (1985) Plasminogen activators,tissue degradation, and cancer. Adv Cancer Res 44:139-266. 2. Andreasen PA, Kjøller L, Christensen L, Duffey MJ (1997) The urokinase plasminogen activator system in cancer metastasis. Int J Cancer 2:1-22. 3. Danø K,et al (2005) Plasminogen activation and cancer. Thromb Haem 93:676-681.4. Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk acording to urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). Cancae Res 62:4617-22. 5. Kaltoft K,et al (1982) Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci USA 79:3720-3723. 6. Nielsen LS, et al (1986). J Immunoassay 7:209-228. 7. Grøndahl-Hansen J, et al (1993)Cancer Res 53:2513-2521.